Vlasov A P, Al-Kubaysi Sh, Vlasova T I, Leshchankina N Yu, Okunev N A, Sheyranov N S, Polozova E I
National Research Mordovia State University, Saransk, Russia.
Khirurgiia (Mosk). 2019(2):65-71. doi: 10.17116/hirurgia201902165.
To evaluate the effectiveness of the Remaxol in the correction of hemostatic system in patients with severe acute peritonitis.
52 patients with acute peritonitis of different severity were examined, and divided into 4 groups: I - mild, II - moderate, III - severe. The patients of these groups had treated using standard therapy. The IV group had patients with severe peritonitis, who received an additional Remaxol. The hemostasis system was evaluated using a TEG 5000 thromboelastograph and biochemical tests.
It has been established that the acute peritonitis is accompanied by significant hemostatic disorders - hypercogulation and hyperfibrinolysis, independently of the disease severity.
In the severe peritonitis, disorders of the coagulation-lytic system were especially expressed. The use of the Remaxol in patients of this group led to a decrease the blood coagulation disorders.
评估瑞马索布（Remaxol）对重症急性腹膜炎患者止血系统的纠正效果。
对52例不同严重程度的急性腹膜炎患者进行检查，并分为4组：I组 - 轻度，II组 - 中度，III组 - 重度。这些组的患者采用标准疗法进行治疗。IV组为重症腹膜炎患者，额外接受瑞马索布治疗。使用TEG 5000血栓弹力图仪和生化检测评估止血系统。
已证实急性腹膜炎伴有明显的止血障碍 - 高凝和高纤溶，与疾病严重程度无关。
在重症腹膜炎中，凝血 - 纤溶系统紊乱尤为明显。该组患者使用瑞马索布可减少血液凝固障碍。
